

Development of a Novel Self-Adjuvanting Vaccine Platform for Tuberculosis (TB)



Andy C. Tran
7th Global Forum on
TB Vaccines, 2024



Protein Subunit Vaccines

✓
Highly
reproducible
and
customisable

✓
Easier to
store

✓
No live
organisms

✗
Requires the
use of
adjuvants

✗
Limited access
to existing
adjuvants

✗
Long duration
from DNA to
cell line to
purified protein

✗
Formulation
and validation
of multiple
components

✗
Licensing
challenges for
existing
adjuvants

✗
Cost of
development
and production



PCF

Platform CTB-Fc

PCF (Platform CTB-Fc)

A novel self-advanting single-polypeptide vaccine platform (Patent in application)

Dengue



SARS-CoV2



TB



CTB


ESAT6/CFP10

HINGE


IgG Fc




Single-chain



Monomer



Polymerisation




Plant Expression System

- Mammalian cell production of recombinant proteins requires sterile conditions and expensive reagents
- Transient expression system using *N. benthamiana* allows for rapid production of large quantities of recombinant protein
- Customisable post-translational modifications (glycosylation profiles) similar to that of mammalian cell systems




In vitro Characterisation of TB-PCF


SDS-PAGE




CTB



Antigen




Myeloid Cell Binding and Internalisation



Aerosolisation

- Safer and more practical than needle-based vaccine delivery
- Can induce mucosal immune response
- Low-cost and widely available devices such as the Omron Micro Air U22
- Aerosolisation process may degrade proteins and affect their function




Aerosolisation

- Safer and more practical than needle-based vaccine delivery
- Can induce mucosal immune response


- Low-cost and widely available devices such as the Omron Micro Air U22

- Aerosolisation process may degrade proteins and affect their function

Protein Recovery by ELISA



Binding to Macrophage Cell Line






In vivo Experiment



UNIVERSITY OF
LEICESTER



Immunogenicity

n=3
C57BL6/J



Efficacy

n=6
PBS, BCG n=7
C57BL6/J





Antibody Responses

Antibody responses against ESAT-6/CFP-10 fusion protein following TB-PCF vaccination in C57BL6/J mice by ELISA

Serum
n=3, 1:50 → 3-fold

Bronchoalveolar Lavage (BAL) Fluid
n=3, IgA = 1:1 → 2-fold. IgG1, IgG2b = 1:2 → 2-fold



Mean of 3 biological replicates, error bars = SEM
y = absorbance 450nm


Antigen Recall

96 hour *ex vivo* antigen recall responses against ESAT-6/CFP-10 fusion protein


Spleen Th1 Responses (IFN- γ , IL-2, TNF- α), n=3

Spleen Th17 Responses (IL-2, IL-17), n=3

CD4
TEM




CD8
TEM




IFN- γ	+	+	+	+	-	-	-
IL-2	+	+	-	-	+	+	-
TNF- α	+	-	+	-	+	-	+

CD4
TEM



CD8
TEM





IL-2	+	-
IL-17	+	+

P = PBS, B = BCG, T = TB-PCF

TB-PCF Efficacy (Modified MGIA)

MGIA = Mycobacterial Growth Inhibition Assay




One way ANOVA, Tukey's Correction
* $P \leq 0.05$
*** $P \leq 0.001$


TB-PCF Efficacy (*in vivo* Aerosol Challenge)



Cull 3-weeks post aerosol TB challenge




Enumerate Lung CFU



One way ANOVA, Tukey's Correction. ** P ≤ 0.01

Summary/Future Work

- TB-PCF forms polymers which can be efficiently internalised by APCs
- TB-PCF can be aerosolised with commonly used excipients
- TB-PCF elicits antigen specific antibody responses in both serum and lung mucosa, as well as Th1 and Th17 responses
- MGIA assay reveals a positive effect of TB-PCF vaccination, although no difference in protection was seen in lung CFU post-aerosol H37Rv challenge so far
- Investigation of other TB antigens in PCF platform



Acknowledgements

St George's, University of London

- Prof. Rajko Reljic
- Dr Mi Young Kim
- Dr Emil Joseph Vergara

University of Leicester

- Prof. Andrea M. Cooper
- Dr John E. Pearl
- Dr Mrinal Das
- Deborah Bursnall
- Lucy Onions
- Marialuisa Crosatti
- University of Leicester PRF

VALIDATE/BMGF Mice



St George's
University of London

INSTITUTE FOR
**INFECTION &
IMMUNITY**



BILL & MELINDA
GATES *foundation*



VALIDATE

Vaccine development for complex
Intracellular neglected pATHogEns

